Compare AEC & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEC | NKTX |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 132.8M |
| IPO Year | N/A | 2020 |
| Metric | AEC | NKTX |
|---|---|---|
| Price | $6.71 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 136.9K | ★ 821.7K |
| Earning Date | 05-01-2015 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $1.31 |
| 52 Week High | $12.49 | $2.74 |
| Indicator | AEC | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 42.32 |
| Support Level | $6.03 | $1.91 |
| Resistance Level | $7.14 | $2.13 |
| Average True Range (ATR) | 0.78 | 0.13 |
| MACD | -0.24 | -0.04 |
| Stochastic Oscillator | 5.23 | 7.70 |
Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One. The company's geographical segments are Canada and the United States.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.